Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.

@article{Yoo2010CrosssectionalSO,
  title={Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.},
  author={Changhoon Yoo and Min-Hee Ryu and Byung Woog Kang and Sung Woo Yoon and Boong Yeol Ryoo and Heung Moon Chang and Joong Shik Lee and Mo Youl Beck and Tae Won Kim and Yoon-koo Kang},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 9},
  pages={
          1554-9
        }
}
PURPOSE Imatinib plasma trough levels (C(min)) have been reported to correlate with treatment outcomes in patients with gastrointestinal stromal tumors (GISTs). We therefore have evaluated the correlation between imatinib C(min) and the clinical characteristics of patients with GIST. PATIENTS AND METHODS Steady-state imatinib C(min) in 107 patients with GIST who were taking imatinib 300 to 800 mg/d was measured. RESULTS In patients treated with imatinib 400 (n = 92), 300 (n = 7), 600 (n = 2… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Similar Papers

Loading similar papers…